



# Pharma Finance 2007

## ROMA - ITALY - MAY 10-11

# 5TH ANNUAL PARTNERING CONFERENCE

### Market Data (AS OF MAY 1, 2007)



Symbol	TSX
Exchange	BMR
Current Price	\$4.00
Shares Outstanding	7.8M
Market Capital	\$30M
52wk RANGE	\$1.65-\$7.00
Average Volume	-
YTD % Change	+44%

### COMPANY FACT SHEET



#### Bradmer Pharmaceuticals

365 Bay Street  
Suite 800  
Toronto, ON M5H 2V1  
(416) 361-6058  
[www.bradmerpharma.com](http://www.bradmerpharma.com)



**Mark C. Rogers (M.D. M.B.A.)**  
Chairman & CEO

### FINANCIAL HIGHLIGHTS (YEAR ENDING DEC 31ST, 2006)

<b>Net Revenue:</b>	N/A	<b>Earnings per Share:</b>	N/A
<b>Net Income:</b>	N/A	<b>Weighted Average:</b>	N/A

### CONFERENCE OBJECTIVES

Actively seeks similar clinical stage cancer therapies for in-licensing and pipeline expansion.

### RECENT DEVELOPMENTS

#### March 23, 2007

Bradmer Pharmaceuticals Hires Vice President of Medical Affairs and Opens Montreal Office

#### March 1, 2007

Bradmer Announces 2006 Fourth Quarter and Fiscal Year Operational and Financial Results

#### February 14, 2007

Bradmer Executive to Present at the Technology Transfer For Biopharmaceuticals Conference

### PRODUCT AND PRODUCT CANDIDATE PIPELINE

Bradmer's novel compound, Neuradiab, addresses one of the key weaknesses in the current therapy regimen for GBM. These tumors typically have infiltrating edges that are very difficult to remove surgically. Externally delivered radiation has limitations given the difficulty in focusing its energy specifically on remaining tumor cells and its potential to harm nearby sensitive and critical tissues. Neuradiab is a monoclonal

antibody conjugated to radioactive iodine (I-131) that is delivered directly into the surgical resection cavity in a separate procedure following the initial surgery. Neuradiab's molecular target is tenascin, a protein that is over-expressed by 99% of all GBM's but is absent from normal brain tissues. Therefore, Neuradiab is able to deliver a concentrated level of radiation specifically to cancer cells that remain following surgical resection.

### Company Description

Bradmer Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new and innovative cancer therapies. Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme (GBM). To date, over US\$60 million in grants and related support has driven research and development of the licensed treatment, which has been delivered to over 200 patients in a series of Phase I and Phase II clinical trials at Duke University. Bradmer intends to launch a multi-center, pivotal Phase III trial of the licensed treatment during 2007.